A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus (T1D)
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2015
At a glance
- Drugs Secukinumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 23 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 06 Mar 2014 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.